AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1-203 (cancelled)

Claim 204 (new) A method comprising the step of:

providing to a consumer an EPO dosing regimen, wherein said regimen maintains at least a serum EPO concentration above a predose level for about 5 to about 30 days between EPO doses.

Claim 205 (new) The method of claim 204, wherein said consumer is a patient.

Claim 206 (new) The method of claim 204, wherein said consumer is a physician.

Claim 207 (new) The method of claim 204, wherein said consumer is a healthcare professional.

Claim 208 (new) The method of claim 204, wherein said serum EPO concentration is sufficient to increase production of red blood cells.

Claim 209 (new) The method of claim 208, wherein said serum EPO concentration is sufficient to maintain increased red blood cell production for at least about one week.

Claim 210 (new) The method of claim 208, wherein said serum EPO concentration is sufficient to maintain increased red blood cell production for at least about two weeks.

Claim 211 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO about once a week.

Claim 212 (new) The method of claim 211, wherein said once a week EPO dosing regimen comprises administering a dose of EPO in the range of about 300 IU/kg to about 2400 IU/kg.

Claim 213 (new) The method of claim 211, wherein said once a week EPO dosing regimen comprises administering a dose of EPO in the range of about 30,000 IU to about 54,000 IU.

Claim 214 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering a dose of EPO about once every two weeks.

Claim 215 (new) The method of claim 214, wherein said once every two weeks EPO dosing regimen comprises administering a dose of EPO in the range of about 900 IU/kg to about 1200 IU/kg.

Claim 216 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO about once every ten days.

Claim 217 (new) The method of claim 216, wherein said once every ten days EPO dosing regimen comprises administering a dose of EPO of about 900 IU/kg.

Claim 218 (new) The method of claim 204, 209, 210, 211, 214, or 216, wherein said EPO dosing regimen comprises administering EPO selected from the group consisting of epoietin alpha and darbepoietin alpha.

Claim 219 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO selected from the group consisting of novel erythropoeisis stimulating protein (NESP), human erythropoietin analog, and erythropoietin omega.

Claim 220 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering proteins having EPO biological activity.

Claim 221 (new) The method of claim 220, wherein said proteins having EPO biological activity are selected from the group consisting of erythropoietin analogs, erythropoietin isoforms, and renal erythropoietin.

Claim 222 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO derived from the group consisting of naturally occurring EPO, recombinant EPO, and synthetic EPO.

Claim 223 (new) The method of claim 205, wherein said patient has anemia.

Claim 224 (new) The method of claim 223, wherein said anemia comprises EPO concentration related anemia.

Claim 225 (new) The method of claim 224, wherein said anemia is selected from the group consisting of end-stage renal failure, renal failure related anemia, and dialysis related anemia.

Claim 226 (new) The method of claim 223, wherein said anemia comprises cancer chemotherapy related anemia.

Claim 227 (new) The method of claim 223, wherein said anemia comprises AIDS drug therapy related anemia.

Claim 228 (new) The method of claim 223, wherein said anemia comprises drug related anemia.

Claim 229 (new) The method of claim 228, wherein said drug is selected from the group consisting of cisplatin and carboplatin.

Claim 230 (new) The method of claim 228, wherein said drug is zidovudine.

Claim 231 (new) The method of claim 205, wherein said patient is undergoing blood donation.

Claim 232 (new) The method of claim 205, wherein said patient has received a bone marrow transplant.

Claim 233 (new) The method of claim 205, wherein said patient has rheumatoid arthritis.

Claim 234 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO via a route selected from the group consisting of intravenous administration, subcutaneous administration, and parental administration.

Claim 235 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO having a modified glycosylation pattern.

Claim 236 (new) The method of claim 235, wherein said EPO having a modified glycosylation pattern comprises darbepoietin alpha.

Claim 237 (new) The method of claim 204 further comprising the step of:

providing EPO in conjunction with said providing to a consumer an EPO dosing regimen.

Claim 238 (new) The method of claim 204, wherein said providing step comprises selling.

Claim 239 (new) The method of claim 237, wherein said providing step comprises selling.

Claim 240 (new) The method of claim 204, wherein said providing step is performed through the use of a computer system.

Claim 241 (new) The method of claim 237, wherein said providing step is performed through the use of a computer system.

Claim 242 (new) The method of claim 204, wherein said EPO is purified hyperglycosylated erythropoietin.

Claim 243 (new) The method of claim 242, wherein said purified hyperglycosylated erythropoietin is hyperglycosylated human erythropoietin.

Claim 244 (new) The method of claim 204, wherein said EPO dosing regimen comprises administering EPO about once every four weeks.